Biosplice announces collaboration with novo nordisk in diabetes

San diego, june 13, 2024 (globe newswire) -- biosplice therapeutics, inc. (“biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of dyrk/clk kinases, has entered a collaboration with novo nordisk to develop drug candidates for the treatment of diabetes.   this agreement builds upon biosplice's innovative research, supported by robust external scientific literature, demonstrating the potential of dyrk inhibition to stimulate Β-cell proliferation in animal models and human islet cells, thus offering a promising avenue for diabetes treatment.
NVO Ratings Summary
NVO Quant Ranking